Patents by Inventor Hiromu Kondo
Hiromu Kondo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240267815Abstract: A system that stores functional information indicating a capability of each of a plurality of elements located remotely from the system; identifies a function capable of being performed by linking a plurality of the elements based on the stored functional information; and transmits information corresponding to the identified function capable of being performed by linking the plurality of elements to a first device remote from the system.Type: ApplicationFiled: April 19, 2024Publication date: August 8, 2024Applicant: Sony Group CorporationInventors: Takehiro HAGIWARA, Hiroyuki MASUDA, Genta KONDO, Hiromu TAKIZAWA
-
Publication number: 20220307769Abstract: The baked object taking-out apparatus is an apparatus that takes out a baked object from a baking base plate including a disposing surface on which the baked object is disposed. The baked object taking-out apparatus includes a robot arm, a holding member that is provided on the robot arm, that is formed of a metal material, and that is capable of holding the baking base plate, and a protective member that is formed at a portion of the holding member which comes into contact with the baking base plate and that is configured with a ceramic coating which contains a ceramic component.Type: ApplicationFiled: March 28, 2022Publication date: September 29, 2022Applicant: Noritake Co., LimitedInventors: Hiromu Kondo, Kenichi Tanaka, Akira Sakai, Hidetaka Kato
-
Publication number: 20120088838Abstract: The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.Type: ApplicationFiled: December 16, 2011Publication date: April 12, 2012Applicant: Astellas Pharma Inc.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Patent number: 8128958Abstract: The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.Type: GrantFiled: May 10, 2004Date of Patent: March 6, 2012Assignee: Astellas Pharma Inc.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20110281906Abstract: A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.Type: ApplicationFiled: August 2, 2011Publication date: November 17, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hiromu Kondo, Hiroyuki Kojima, Keiichi Yoshihara, Yuko Taketani, Takuya Ishii
-
Publication number: 20110142933Abstract: A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration.Type: ApplicationFiled: January 19, 2011Publication date: June 16, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOJIMA, Hiromu KONDO, Keiichi YOSHIHARA, Yuko TAKETANI, Takuya ISHII
-
Publication number: 20090239791Abstract: A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects.Type: ApplicationFiled: October 23, 2008Publication date: September 24, 2009Applicant: Astellas Pharma Inc.Inventors: Takayuki Yoshida, Kiyo Nakanishi, Atsushi Maeda, Kazuhiro Sako, Yuki Kasashima, Hiromu Kondo, Tatsunobu Yoshioka, Yuuki Tsutsui
-
Publication number: 20090011018Abstract: A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.Type: ApplicationFiled: December 26, 2007Publication date: January 8, 2009Inventors: Hiromu Kondo, Hiroyuki Kojima, Keiichi Yoshihara, Yuko Taketani, Takuya Ishii
-
Publication number: 20080181947Abstract: A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration.Type: ApplicationFiled: September 25, 2007Publication date: July 31, 2008Inventors: Hiroyuki Kojima, Hiromu Kondo, Keiichi Yoshihara, Yuko Taketani, Takuya Ishii
-
Publication number: 20080131511Abstract: [Problem] An agent for treating eye and mouth dryness, which does not accompanies undesirable actions is provided. [Means for Resolution] Administration of the compound A made it possible to accelerate tear and salivary fluid secretion without accompanying sweating and its sustained release administration enabled acceleration of lacrimal gland and salivary gland cell growth as well.Type: ApplicationFiled: September 26, 2007Publication date: June 5, 2008Inventors: Yohei Okada, Ken Ikeda, Fumikazu Wanibuchi, Keiichi Yoshihara, Hiromu Kondo, Hiroyuki Kojima
-
Publication number: 20070105934Abstract: [Problem]An agent for treating eye and mouth dryness, which does not accompanies undesirable actions is provided. [Means for Resolution]Administration of the compound A made it possible to accelerate tear and salivary fluid secretion without accompanying sweating and its sustained release administration enabled acceleration of lacrimal gland and salivary gland cell growth as well.Type: ApplicationFiled: October 4, 2005Publication date: May 10, 2007Inventors: Yohei Okada, Ken Ikeda, Fumikazu Wanibuchi, Keiichi Yoshihara, Hiromu Kondo, Hiroyuki Kojima
-
Patent number: 7008640Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: GrantFiled: July 16, 2001Date of Patent: March 7, 2006Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20050100603Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an ?1 receptor blocking action are reduced.Type: ApplicationFiled: May 10, 2004Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20020150624Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: ApplicationFiled: July 16, 2001Publication date: October 17, 2002Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada